Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label erlotinib in advanced/metastatic or recurrent NSCLC (JO18396)
jRCT2080220075Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080220075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220075.